Gilead provides upbeat 2025 forecast, shares rise 4%
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
FiercePharma2d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Gilead Sciences (NASDAQ:GILD) Hits New 12-Month High on Earnings Beat
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
Gilead Quarterly Results Beat Estimates
Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...
STAT2d
Gilead’s short-term win threatens the future of pharmaceutical public-private partnerships
The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...